Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

ClinicalTrials.gov ID: NCT03888612

Public ClinicalTrials.gov record NCT03888612. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Study identification

NCT ID
NCT03888612
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Arvinas Inc.
Industry
Enrollment
248 participants

Conditions and interventions

Interventions

  • ARV-110 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2019
Primary completion
Apr 28, 2024
Completion
Jan 26, 2025
Last update posted
Mar 31, 2025

2019 – 2025

United States locations

U.S. sites
54
U.S. states
14
U.S. cities
54
Facility City State ZIP Site status
Clinical Trial Site Los Angeles California 90095
Clinical Trial Site Orange California 92868
Clinical Trial Site San Francisco California 94158
Clinical Trial Site New Haven Connecticut 06510
Clinical Trial Site Altamonte Springs Florida 32701
Clinical Trial Site Bonita Springs Florida 34135
Clinical Trial Site Bradenton Florida 34211
Clinical Trial Site Brandon Florida 33511
Clinical Trial Site Cape Coral Florida 33939
Clinical Trial Site Clearwater Florida 33761
Clinical Trial Site Daytona Beach Florida 32117
Clinical Trial Site Fleming Island Florida 32003
Clinical Trial Site Fort Myers Florida 33908
Clinical Trial Site Gainesville Florida 32605
Clinical Trial Site Largo Florida 33770
Clinical Trial Site Lecanto Florida 34461
Clinical Trial Site Naples Florida 34102
Clinical Trial Site New Port Richey Florida 34655
Clinical Trial Site Ocala Florida 34474
Clinical Trial Site Orange City Florida 32763
Clinical Trial Site Orlando Florida 32806
Clinical Trial Site Port Charlotte Florida 33980
Clinical Trial Site Sarasota Florida 34236
Clinical Trial Site Spring Hill Florida 34608
Clinical Trial Site St. Petersburg Florida 33705
Clinical Trial Site Stuart Florida 34994
Clinical Trial Site Tampa Florida 33607
Clinical Trial Site Tavares Florida 32778
Clinical Trial Site The Villages Florida 32159
Clinical Trial Site Venice Florida 34292
Clinical Trial Site Vero Beach Florida 32960
Clinical Trial Site Wellington Florida 33414
Clinical Trial Site West Palm Beach Florida 33401
Clinical Trial Site Winter Park Florida 32792
Clinical Trial Site Chicago Illinois 60611
Clinical Trial Site New Orleans Louisiana 70112
Clinical Trial Site Boston Massachusetts 02114
Clinical Trial Site Detroit Michigan 48201
Clinical Trial Site Omaha Nebraska 68130
Clinical Trial Site Las Vegas Nevada 89169
Clinical Trial Site New York New York 10065
Clinical Trial Site Portland Oregon 97239
Clinical Trial Site Dickson Tennessee 37055
Clinical Trial Site Franklin Tennessee 37067
Clinical Trial Site Gallatin Tennessee 37066
Clinical Trial Site Hendersonville Tennessee 37075
Clinical Trial Site Hermitage Tennessee 37076
Clinical Trial Site Lebanon Tennessee 37090
Clinical Trial Site Murfreesboro Tennessee 37129
Clinical Trial Site Nashville Tennessee 37211
Clinical Trial Site Shelbyville Tennessee 37160
Clinical Trial Site Smyrna Tennessee 37167
Clinical Trial Site Salt Lake City Utah 84112
Clinical Trial Site Charlottesville Virginia 22903

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03888612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 31, 2025 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03888612 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →